Limitations of current treatment: Unmet needs in the treatment of COPD;Limitaciones del tratamiento actual: Necesidades no cubiertas en el tratamiento de la EPOC

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.10, 2010, Pages 8-13

  De Lucas Ramos, Pilar ^a   Martín, Soledad López ^a   González Moro, José Miguel Rodríguez ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antiinflammatory agents; Bronchodilators; COPD; Rehabilitation; Smoking

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; ROFLUMILAST;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; PULMONARY REHABILITATION; QUALITY OF LIFE; RELAPSE; SMOKING CESSATION;

ADRENAL CORTEX HORMONES; AIRWAY OBSTRUCTION; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; OXIDATIVE STRESS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION;

EID: 79851491511     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70050-8     Document Type: Article

References (54)

1. Miravitlles M., Soriano J.B., García Río F., Muñoz K., Durán Tauleria E., Sánchez G., et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868.
2. Sobradillo Peña V., Miravitlles M., Gabriel R., Jiménez Ruiz C.A., Villasante C., Masa J.F., et al. Geographic variations in prevalence and underdiagnosis of COPD. Chest 2000, 118:981-989.
3. Celli B. EPOC: desde el nihilismo no justificado a un optimismo razonable. Arch Bronconeumol 2002, 38:585-588.
4. Chronic obstructive pulmonary disease. National clinical guidelines on management of chronic obstructive pulmonary diseasein adults in primary and secondary care. Thorax 2004, 59(Suppl 1):S1-232. National Collaborating Centre for Chronic Conditions.
5. Celli B.R., MacNee W. Standards for the diagnosis ant treatment of patients with COPD. A summary of the ATS-ERS position paper. Eur Respir J 2004, 23:932-946. and committee members.
6. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía Clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
7. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007:176:532-55 (). Update 2009. http://www.goldcopd.org.
8. Ram F.S.F., Sestini P. Regular inhaled short-acting β2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003, 58:580-584.
9. Appleton S., Poole P., Smith B., Veale A., Bara A. Long-acting beta-2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation (Cochrane Review). The Cochrane Lybrary, Issue 1 2004, John Wiley & Sons, Ltd, Chichester, UK.
10. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library, Issue 1, 2005; Oxford: Update Software.
11. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropio inhalado para la enfermedad pulmonar obstructiva crónica estable. Revisión Cochrane traducida. En: La Biblioteca Cochrane Plus 2006, Número 2. Oxford: Update Software Ltd. Disponible en: htpp://www.update-software.com (Traducida de The Cocrhane Library, 2006 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
12. Jiménez Ruiz CA, De Lucas Ramos P, Díaz Lobato S, García Carmona T, Losada Molina C, Martínez Verdasco A, y Grupo de Estudio TOMA. Estudio sobre la prevalencia y actitudes sobre tabaquismo en los pacientes sometidos a oxigenoterapia crónica en la Comunidad de Madrid. Estudio TOMA. Arch Bronconeumol. 2010. (En prensa.).
13. Anthonisen N.R., Connet J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S. Effects of smoking intervention and the use of an inhaled anticholenergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505.
14. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connet J.E. The effects of a smoking cessation intervention on a 14.5 year mortality. Ann Intern Med 2005, 142:233-239.
15. Wagena E.J., Knipschild P.G., Huiber M.JH., Wouters E.FM., Schayck C.P. Efficacy of bupropion and nortriptiline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005, 165:2286-2292.
16. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in mild to moderate COPD: A randomized controlled trial. Chest. 2010, Sep 23. (En prensa.).
17. Johnson M., Rennard S. Alternative mechanism for long-acting b2-adrenergic agonists in COPD. Chest 2001, 120:258-270.
18. Dahl R., Greefhorst L.APM., Nowak D., Nonikov V., Byrne A.M., Thomson M.H., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
19. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069.
20. Calverley P., Pawela R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003, 361:449-456.
21. O'Donnell D.E., Voduc N., Fitzpatric M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94.
22. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
23. Vincken W., Van Noord J.A., Greefhorst A.PM., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002, 19:209-216.
24. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
25. Dahl R., Ching K.F., Buhl R., Magnussen H., Nonikov V., Jack D., et al. Efficacy of a new once-daily long-acting in haled beta2-agonist indacterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. on behalf of INVOLVE (Indacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) study investigators.
26. Donohue J.F., Fogarty C., Lötwall J., Mahler D.A., Worth H., Yorgancioglu A., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. on behalf of INHANCE study investigators.
27. Kommann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: A placebo-controlled comparison. Eur Respir J. 2010. (En prensa.).
28. Tashkin DP, Varghese ST. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharm Ther. 2010 (En prensa.).
29. Berton D.C., Reis M., Siqueira A.C., Barroco A.C., Takara L.S., Bravo D.M., et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010, 104:1288-1296.
30. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. on behalf of UPLIFT study investigators.
31. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000, 343:269-280.
32. Cosío Piqueras F.B.G. Etiopatogenia de la EPOC. Biblioteca EPOC 1: Concepto y Patogenia 2004, 45-70. Ergon, Madrid. P. de Lucas, J.M.R. González-Moro (Eds.).
33. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:342-344.
34. Paggiaro P.L., Dahle R., Bakran I., Hollingworth K., Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998, 351:773-780.
35. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999, 353:1819-1823.
36. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999, 340:1948-1953.
37. Burge P.S., Calverley P.MA., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. the ISOLDE trial. Br Med J 2000, 320:1297-1303.
38. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902-1909. The Lung Health Study research group.
39. Szafransky W., Cukier A., Ramírez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81.
40. Calverley P., Pawels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled. Lancet 2003, 361:449-456.
41. Calverley P.MA., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. on behalf of TORCH investigators.
42. Barnes P.J., Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004, 364:985-996.
43. Yokomizo T., Kato K., Terawaki K., Izumi T., Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000, 192:421-432.
44. Yang X.D., Corvalan J.R., Wang P., Roy C.M., Davis C.G. Fully human anti-interleukin- 8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999, 66:401-410.
45. White J.R., Lee J.M., Young P.R., Hertzberg R.P., Jurewicz A.J., Chaikin M.A., et al. Identification of a potent, selective nonpeptide CXCR2 antagonist that inhibits interleukin- 8-induced neutrophil migration. J Biol Chem 1998, 273:1095-1098.
46. Hay D.WP., Sarau H.M. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol 2001, 1:242-247.
47. Matera M.G., Calzetta M., Cazzola M. TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulm Pharacol Ther 2010, 23:121-128.
48. Decramer M., Rutten van Molken M., Dekhuijzen P.N., Troosters T., Van Herwaarden C., Pellegrino R., et al. Effects of N acetylcysteina on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on NAC Cost-Utility Study, BRONCUS) a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
49. Cortijo Gimeno J., Morcillo Sánchez E. Perfil farmacológico del roflumilast. Arch Bronconeumol 2010, 46.
50. Izquierdo Alonso J.L. Perfil clínico del roflumilast. Arch Bronconeumol 2010, 46.
51. Calverley P.M., Rabe K.F., Goehring U.W., Kristiansen S., Fabri L.M., Martínez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomized clinical trials. Lancet 2009, 374:685-694. on behalf of M2-124 y M2-125 study groups.
52. Fabri L.M., Calverley P.M., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martínez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomized clinical trials. Lancet 2009, 374:695-703. on behalf of M2-127 y M2-128 study groups.
53. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003793. DOI:10.1002/14651858.CD003793.pub2.
54. Ambrosino N., Casaburi R., Ford G., Goldstein R., Morgan M.DL., Rudolf M., et al. Developing concepts in the pulmonary rehabilitation of COPD. Respir Med 2008, 102(Suppl 1):S17-26.